AusBiotech 2013
“Brokers meet Biotech”
CALZADA LIMITED
ASX:CZD September 2013
AusBiotech 2013 Brokers meet Biotech CALZADA LIMITED ASX:CZD - - PowerPoint PPT Presentation
AusBiotech 2013 Brokers meet Biotech CALZADA LIMITED ASX:CZD September 2013 Disclaimer Disclaimer This presentation has been prepared by Calzada Limited and is provided for general information purposes only. No party other than
ASX:CZD September 2013
Disclaimer
This presentation has been prepared by Calzada Limited and is provided for general information purposes only. No party other than Calzada has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment
to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward looking statements) expressed in this presentation are subject to change without notice. Calzada and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, or contained in or derived from, or for any
This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect
jurisdiction in which, or to any person to whom, such an offer would be illegal.
Forward-looking statements
This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Calzada. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Calzada or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.
Directors
David Franklyn Chairman Bruce Rathie Non Exec. David McQuillan Non Exec.
Calzada LTD
ASX Code CZD Share Price 7.3 cents Issued Shares 406m Market Cap. $30 million Cash on Hand* $6.2 million
Major Shareholders
Merchant Funds 16% Management 8% Monash / Frank Ng 4%
*Includes estimated R&D tax concession
PolyNovo’s biodegradable polymer technology, NovoSorbTM, has applications as a tissue scaffold and for use in reconstructive surgery.
Foam Polymers Other Polymers
Facial Augment.
NovoSorbTM
TNP Dermal Pelvic Hernia Ortho- Cardio- Bone Void Drug Wound Replace- Floor Repair paedic vascular Fillers eluting Dressings ment Repair implants Stents coatings
s lead products are based around the NovoSorbTM biodegradable foam which has applications as a tissue scaffold in:
as a tissue scaffold:
How does it work ?
BTM in third degree burn Tissue integration at day 3 BTM fully integrated at day 10 Ready for skin grafting Skin graft on integrated BTM
Repair of a surgical wound – NovoSorbTM BTM
Day 0 (33.5cm2) Day 0 post BTM Implantation Day 5 (31.7cm2) Day 14 (35.6cm2) Day 21 Post delamination Day 21 Post grafting Three months post grafting Six weeks post grafting (23.1cm2) Six months post grafting
Repairing Surgical Wounds – with and without BTM
Skin graft directly over wound – current treatment Wound treated with NovoSorb™ BTM foam
Human Trials Regulatory US Commercialisation Market Size TNP foam Completed 510(k) submitted Discussions underway ~$400M Surgical wounds Completed 510(k) submission by Q1 2014 Preliminary discussions Burns Further required PMA Preliminary discussions ~$100M+ Hernia Partner Responsibility 510(k) Feasibility Agreement with US based group ~$1000M Facial Augmentation Partner Responsibility 510(k) Joint venture ~$1000M
Growth Hormone activates both the IGF-1 (crossed out) and direct cellular
significant insulin resistance and other negative side-effects.
2nd hormone - IGF1 (made in the liver)
Fat
AOD9604
Growth hormone fragment
(only 8% of the GH molecule)
Bone
Muscle and Organ growth Bone length Protein synthesis
Burns fat, Inhibits storage IGF-1 and pro-diabetic effects removed
Cartilage & Muscle
Promotes repair IGF-1 pathway Direct cellular pathway
AOD is legally available in Australia if prescribed by a Doctor and prepared by a compounding pharmacy Metabolic investigating opportunity to license compounding chemists Potential to deliver short term cash flow
Draft trial protocol being prepared
Requirement for further publications